TY - JOUR
T1 - Treatment for food allergy
T2 - Current status and unmet needs
AU - Dantzer, Jennifer A.
AU - Kim, Edwin H.
AU - Chinthrajah, R. Sharon
AU - Wood, Robert A.
N1 - Funding Information:
Genentech, Inc, a member of the Roche Group, funded medical writing assistance, which was provided by Janelle Keys, PhD, CMPP, of Envision Pharma Group. Envision's services complied with international guidelines for Good Publication Practice. Genentech, Inc, was not involved in any aspects of manuscript preparation. Disclosure of potential conflict of interest: J.A. Dantzer reports research funding from National Institute of Allergy and Infectious Disease. E.H. Kim is an advisory board member for ALK-Abello, DBV Technologies, Kenota Health, and Ukko Inc; is a consultant for AllerGenis, Allergy Therapeutics Ltd, Belhaven Pharma, Duke Clinical Research Institute, Genentech, and Nutricia; and receives grant support to his university from Food Allergy Research and Education and National Institutes of Health. R.S. Chinthrajah receives grant support from Aimmune, Astellas, AstraZeneca, the Consortium for Food Allergy Research, Food Allergy Research and Education, DBV Technologies, the National Institute of Allergy and Infectious Disease, Novartis, and Regeneron; and is an advisory board member for Alladapt Immunotherapeutics, Allergenis, Genentech Intrommune Therapeutics, Novartis, and Sanofi. R.A. Wood receives research support from the National Institutes of Health, Food Allergy Research and Education, Aimmune, DBV Technologies, Genentech, Novartis, Sanofi, Regeneron, and Siolta; and receives royalty fees from Up To Date.
Funding Information:
Disclosure of potential conflict of interest: J.A. Dantzer reports research funding from National Institute of Allergy and Infectious Disease. E.H. Kim is an advisory board member for ALK-Abello, DBV Technologies, Kenota Health, and Ukko Inc; is a consultant for AllerGenis, Allergy Therapeutics Ltd, Belhaven Pharma, Duke Clinical Research Institute, Genentech, and Nutricia; and receives grant support to his university from Food Allergy Research and Education and National Institutes of Health. R.S. Chinthrajah receives grant support from Aimmune, Astellas, AstraZeneca, the Consortium for Food Allergy Research, Food Allergy Research and Education, DBV Technologies, the National Institute of Allergy and Infectious Disease, Novartis, and Regeneron; and is an advisory board member for Alladapt Immunotherapeutics, Allergenis, Genentech Intrommune Therapeutics, Novartis, and Sanofi. R.A. Wood receives research support from the National Institutes of Health, Food Allergy Research and Education, Aimmune, DBV Technologies, Genentech, Novartis, Sanofi, Regeneron, and Siolta; and receives royalty fees from Up To Date.
Publisher Copyright:
© 2022 American Academy of Allergy, Asthma & Immunology
PY - 2023/1
Y1 - 2023/1
N2 - The treatment of food allergy has traditionally relied on avoidance of the offending food(s) and use of emergency medications in the event of accidental exposures. However, this long-standing paradigm is beginning to shift, as a variety of treatment approaches have been and are being developed. This report provides an overview of the past, present, and future landscape of interventional clinical trials for the treatment of food allergy. It focuses on specific issues related to participant characteristics, protocol design, and study end points in the key clinical trials in the literature and examine how differences between studies may impact the clinical significance of the study results. Recommendations are provided for the optimization of future trial designs and focus on specific unmet needs in this rapidly evolving field.
AB - The treatment of food allergy has traditionally relied on avoidance of the offending food(s) and use of emergency medications in the event of accidental exposures. However, this long-standing paradigm is beginning to shift, as a variety of treatment approaches have been and are being developed. This report provides an overview of the past, present, and future landscape of interventional clinical trials for the treatment of food allergy. It focuses on specific issues related to participant characteristics, protocol design, and study end points in the key clinical trials in the literature and examine how differences between studies may impact the clinical significance of the study results. Recommendations are provided for the optimization of future trial designs and focus on specific unmet needs in this rapidly evolving field.
KW - Food allergy
KW - IgE monoclonal antibodies
KW - biologics
KW - epicutaneous immunotherapy
KW - omalizumab
KW - oral immunotherapy
KW - sublingual immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85139077931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139077931&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2022.08.008
DO - 10.1016/j.jaci.2022.08.008
M3 - Article
C2 - 35998790
AN - SCOPUS:85139077931
SN - 0091-6749
VL - 151
SP - 1
EP - 14
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 1
ER -